(secondQuint)Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma.

 A Phase II Multicenter,Open-Label, Clinical And Pharmacokinetic Study Of Aplidin(R) As A 1-Hour Weekly IV Infusion, In Patients With Relapsed Or Refractory aggressive non-Hodgkin's Lymphoma.

 Primary cent To assess the anti-tumour activity of Aplidin(R) given as a 1-hour weekly IV infusion, in patients with aggressive non-Hodgkin's Lymphoma, relapsing or refractory to a prior therapy.

 Secondary - To further investigate the safety profile of Aplidin(R) given as 1-hour weekly IV infusion in this patient population.

 - To obtain additional pharmacokinetic information for Aplidin(R) given as 1-hour weekly IV infusion in patients with aggressive non-Hodgkin's Lymphoma.

.

 Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma@highlight

This is a multicenter study to assess the anti-tumour activity,to investigate the safety profile and to obtain additional pharmacokinetic information for Aplidin(R) given as 1-hour weekly IV infusion in patients with aggressive non-Hodgkin's Lymphoma.

